200 related articles for article (PubMed ID: 31013494)
1. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
[TBL] [Abstract][Full Text] [Related]
2. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
[TBL] [Abstract][Full Text] [Related]
4. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
6. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
7. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
8. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
9. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
10. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
[TBL] [Abstract][Full Text] [Related]
11. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
[No Abstract] [Full Text] [Related]
12. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
13. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
14. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
16. Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.
van de Meeberg MM; Verheij ER; Fidder HH; Bouma G; Huitema ADR; Oldenburg B
Ther Drug Monit; 2023 Oct; 45(5):668-675. PubMed ID: 36823707
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration.
Kawashima K; Ishihara S; Yuki T; Onishi K; Kushiyama Y; Fujishiro H; Miyaoka Y; Yuki M; Komazawa Y; Tanimura T; Sonoyama H; Tada Y; Kusunoki R; Oka A; Fukuba N; Oshima N; Moriyama I; Kinoshita Y
Biomed Res Int; 2014; 2014():342751. PubMed ID: 25478568
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
19. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
20. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]